Skip to main content
OpenTrials
Completed

NCT Number: NCT06119425

Blood-Based Colorectal Cancer (CRC) Screening Implementation Into Clinical Practice Highlands

This is a prospective implementation study that will include patients that are identified as being average risk for colorectal cancer (CRC) according to USPSTF guidelines and who have opted to be screened for CRC. The purpose of this study is to understand implementation of a noninvasive screening test in primary care and internal medicine clinical settings, and the impact on patient acceptability and adherence of CRC screening.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cancer Colon Colonic Diseases Colonic Neoplasms Colorectal Neoplasms Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Intestinal Diseases Intestinal Neoplasms Neoplasms Neoplasms by Site

Age range

45 year–84 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Johnson City Medical Center

Johnson City, Tennessee, 37604, United States

About this study

Study Rationale This is a prospective implementation study that will include patients that are identified as being average risk for colorectal cancer (CRC) according to USPSTF guidelines and who have opted to be screened for CRC. The purpose of this study is to understand implementation of a noninvasive screening test in primary care and internal medicine clinical settings, and the impact on patient acceptability and adherence of CRC screening.

Although multiple screening options for CRC are available, participation and adherence to CRC screening remains below the national goal. CRC screening rate at the Ballad Health Mountain Laurel Internal Medicine clinic (site 1) is approximately 66%.

A blood-based test (BBT) can provide a clinically important complement to standard-of-care (SOC) screening tests and address unmet medical needs for patients, especially for those who are non-adherent with current screening modalities. There are economic and societal benefits in early detection and prevention of CRC in a broader population than the one currently up to date with screening. The unmet need for maximum participation in CRC screening could be addressed with blood-based testing.

Measuring subsequent provider experience and implementation behavior patterns involving blood based non-invasive cancer screening choices will also help to identify clinical utility of such test and implementation into clinical practice.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged 45-84 years of age (inclusive)
  • Considered by health-care providers to be "average risk" for CRC as determined by USPSTF guidelines
  • If a patient opts for blood-based test, they are able and willing to provide blood samples per protocol
  • Ability to understand and the willingness to participate in the study

Exclusion criteria

  • Patients with a personal history of CRC
  • Patients with a known high-risk family history of CRC precluding the patient from being average risk
  • Patients with known diagnosis of inflammatory bowel disease or history of polyps
  • Patients who are currently symptomatic for CRC such as: blood in the stool
  • Patients with any known medical condition which, in the opinion of the investigator, should preclude enrollment into the study
  • Have a recorded up to date CRC screening
  • Patients with a previous abnormal colonoscopy finding who are due for surveillance.

Treatment and study plan

blood-based CRC screening

Diagnostic Test

For this study, a commercially available blood-based CRC screening test will be used. The selected test is Shield (Guardant Health, Redwood City, California, USA). The Shield test was developed, and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, California, USA, which is certified under the Clinical Laboratory Improvement Act of 1988 (CLIA) as qualified to perform high complexity clinical testing. The Shield test is currently commercially available as an laboratory developed test (LDT). Additionally, Guardant submitted the pre-market approval (PMA) application for the Shield test to the Food and Drug Administration (FDA) in March of 2023. Premarket approval (PMA) is the FDA process of scientific and regulatory review to evaluate the safety and effectiveness of medical devices. To this end, the Shield test is currently under review by the FDA.

Primary outcomes

  1. Opted to be screened for CRC by either SOC or study diagnostic test

    Time frame: 3 months

    Number of participants who agree to be screened CRC. % of participants who agree to be screened for CRC.

Secondary outcomes

  1. Opted to be screened by the study diagnostic test

    Time frame: 3 months

    Number of participants who opted to be screened by the study diagnostic test instead of

Sponsors and collaborators

Lead sponsor

Ballad Health

Other

Collaborators

  • Guardant Health, Inc.

Registry information

Official study title

Blood-Based Colorectal Cancer (CRC) Screening Implementation Into Clinical Practice in the Outpatient Clinical Settings in the Appalachian Highlands

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
Nov 7, 2023
Registry last updated
Feb 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.